Target ALS has launched a new website that offers improved accessibility to patients, researchers, and the ALS community at ...

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS and Parkinson's.

Neurizon hopes to initiate its regimen of the HEALEY-ALS trial in Q4 2025. Image credit: MAXIMUM ART / Shutterstock.com The US Food and Drug Administration (FDA) has released its clinical hold on ...

University of Utah researchers at the Pulst-Scoles Laboratory have discovered that reducing levels of the STAUFEN-1 protein ...

For more than 60 years, this blank slate approach has been the Food and Drug Administration’s gold standard — and for good ...

A look at Amyotrophic Lateral Sclerosis (ALS), focusing on motor neuron degeneration, sporadic versus familial ...

This funding was awarded through the ALS Association's Hoffman ALS Clinical Trial Awards Program, which aims to accelerate the development of new ALS treatments ARLINGTON, Va., Dec. 4, 2025 ...

NEALS, the world's largest ALS research consortium, has selected the COYA 302 trial and it is now affiliated with NEALS as part of its mission to accelerate the development of new treatments for ...

The US Food and Drug Administration (FDA) has released its clinical hold on Neurizon Therapeutics’ NUZ‑001, paving the way for its advancement to the HEALEY-ALS trial. The company’s lead drug in ...